149 related articles for article (PubMed ID: 20128663)
1. Comparative costs of hospitalisation among infants at high risk for respiratory syncytial virus lower respiratory tract infection during the first year of life.
Forbes ML; Hall CB; Jackson A; Masaquel AS; Mahadevia PJ
J Med Econ; 2010 Mar; 13(1):136-41. PubMed ID: 20128663
[TBL] [Abstract][Full Text] [Related]
2. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
[TBL] [Abstract][Full Text] [Related]
3. Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants.
Shi N; Palmer L; Chu BC; Katkin JP; Hall CB; Masaquel AS; Mahadevia PJ
J Med Econ; 2011; 14(3):335-40. PubMed ID: 21524154
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada.
Paes B; Cole M; Latchman A; Pinelli J
Curr Med Res Opin; 2009 Sep; 25(9):2191-6. PubMed ID: 19604126
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
[TBL] [Abstract][Full Text] [Related]
8. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection.
Greenough A; Alexander J; Burgess S; Bytham J; Chetcuti PA; Hagan J; Lenney W; Melville S; Shaw NJ; Boorman J; Coles S; Turner J; Pang F
Arch Dis Child; 2004 Jul; 89(7):673-8. PubMed ID: 15210503
[TBL] [Abstract][Full Text] [Related]
9. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan.
Kaneko M; Watanabe J; Kuwahara M; Ueno E; Hida M; Kinoshita A; Sone T
J Infect; 2002 May; 44(4):240-3. PubMed ID: 12099731
[TBL] [Abstract][Full Text] [Related]
10. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
[TBL] [Abstract][Full Text] [Related]
11. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
12. Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life.
Escobar GJ; Ragins A; Li SX; Prager L; Masaquel AS; Kipnis P
Arch Pediatr Adolesc Med; 2010 Oct; 164(10):915-22. PubMed ID: 20921348
[TBL] [Abstract][Full Text] [Related]
13. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Reeve CA; Whitehall JS; Buettner PG; Norton R; Reeve DM; Francis F
J Paediatr Child Health; 2006 May; 42(5):253-8. PubMed ID: 16712554
[TBL] [Abstract][Full Text] [Related]
15. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus risk factors in late preterm infants.
Lanari M; Silvestri M; Rossi GA
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
[TBL] [Abstract][Full Text] [Related]
17. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants.
Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
Curr Med Res Opin; 2011 Feb; 27(2):403-12. PubMed ID: 21192761
[TBL] [Abstract][Full Text] [Related]
18. Impact of RSV: implications for managed care.
Makari D; Hoopes JM; White N
Manag Care; 2009 Jan; 18(1 Suppl 2):2-7. PubMed ID: 19230529
[TBL] [Abstract][Full Text] [Related]
19. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
20. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
